Leerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24
RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13
Helios Technologies (HLIO) Upgraded by KeyBanc on New Strategy and Leadership Promise
RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT